Phenomics Australia CEO, Dr Michael Dobbie, attended the IMPC-Infrafrontier meeting, hold in a hybrid format, that took place in Seoul, Korea from Sunday 8 May to Tuesday 10 May 2022.
Insights into the gene function that IMPC and INFRAFRONTIER have consistently explored through mouse models play a crucial role in advancing biomedical science.
The meeting brought together IMPC and INFRAFRONTIER delegates across the globe, as well as domestic experts from academia, research institutes, industries and the government, to comprehensively explore and discuss bioresources for genomic medicine. This hybrid gathering, which will resume in about two years, also enabled participants to inspire vigorous and fruitful discussion, elaborate on their ongoing and future study and build a meaningful global network with each other.
The meeting was full of interesting discussions, and talks about different topics including rare diseases and Omics in mouse models, non-coding genes, microbiome, and metabolic dysregulations.
More information about the program can be found here.
Phenomics Australia is a International Mouse Phenotyping Consortium (IMPC) member.
